Vestal Point Capital LP Raises Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Vestal Point Capital LP boosted its holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX) by 67.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 710,000 shares of the company’s stock after buying an additional 285,000 shares during the period. Vestal Point Capital LP owned 1.30% of Bicara Therapeutics worth $12,368,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Wexford Capital LP purchased a new position in Bicara Therapeutics in the fourth quarter worth about $348,000. Red Tree Management LLC bought a new position in Bicara Therapeutics in the fourth quarter worth approximately $55,230,000. Nuveen Asset Management LLC bought a new position in Bicara Therapeutics in the fourth quarter worth approximately $436,000. Orbimed Advisors LLC grew its holdings in Bicara Therapeutics by 9.7% in the fourth quarter. Orbimed Advisors LLC now owns 298,301 shares of the company’s stock worth $5,196,000 after purchasing an additional 26,391 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Bicara Therapeutics by 28.7% in the fourth quarter. Millennium Management LLC now owns 385,406 shares of the company’s stock worth $6,714,000 after purchasing an additional 85,847 shares during the last quarter.

Bicara Therapeutics Price Performance

BCAX stock opened at $14.47 on Monday. Bicara Therapeutics Inc. has a 52 week low of $8.91 and a 52 week high of $28.09. The company’s 50-day moving average price is $12.81 and its 200 day moving average price is $15.20.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). On average, research analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BCAX has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. HC Wainwright lowered their target price on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating on the stock in a research note on Friday. Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, Wells Fargo & Company assumed coverage on shares of Bicara Therapeutics in a report on Thursday, April 17th. They issued an “underweight” rating and a $8.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.